{"nctId":"NCT02612909","briefTitle":"A Safety and Immunogenicity Study of IVACFLU-A/H5N1","startDateStruct":{"date":"2017-03-07","type":"ACTUAL"},"conditions":["Avian Influenza"],"count":930,"armGroups":[{"label":"Phase 2: Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]},{"label":"Phase 2: Vaccine (15 mcg)","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: IVACFLU-A/H5N1 vaccine"]},{"label":"Phase 2: Vaccine (30 mcg)","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: IVACFLU-A/H5N1 vaccine"]},{"label":"Phase 3: Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]},{"label":"Phase 3: Vaccine","type":"EXPERIMENTAL","interventionNames":["Biological: IVACFLU-A/H5N1 vaccine"]}],"interventions":[{"name":"IVACFLU-A/H5N1 vaccine","otherNames":[]},{"name":"Placebo","otherNames":["Sterile Phosphate Buffered Saline (PBS)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female adult 18 through 60 years of age at the enrollment visit.\n* Literate (by self-report) and willing to provide written informed consent.\n* Healthy adults, as established by the medical history and screening evaluations, including physical examination, capable and willing to complete Diary Cards, and willing to return for all follow-up visits.\n* For females able to become pregnant, willing to utilize reliable birth control measures (intrauterine device, hormonal contraception, condoms) through the Day 43 visit.\n\nExclusion Criteria:\n\n* Participation in another clinical trial involving any vaccine or therapy within the previous three months, or planned enrollment in such a trial during the period of this study.\n* Received any non-study vaccine within 4 weeks prior to enrollment or refused to postpone receipt of such vaccines until after the Day 43 visit.\n* Current or recent (within 2 weeks of enrollment) acute illness with or without fever.\n* Received immune globulin or other blood products within 3 months prior to study enrollment or planned receipt of such products prior to the Day 43 visit.\n* Chronic administration (defined as more than 14 consecutively-prescribed days) of immunosuppressants or other immune-modulating therapy within six months prior to study enrollment. (For corticosteroids, this meant prednisone or equivalent, 0.5 mg per kg per day; topical or intranasal steroids were allowed.)\n* History of asthma.\n* Hypersensitivity after previous administration of any vaccine.\n* Suspected or known hypersensitivity to any of the study vaccine components, including chicken or egg protein, antibiotics, and rubber (from the vaccine vial stoppers).\n* Acute or chronic clinically significant pulmonary, cardiovascular, hepatobiliary, metabolic, neurologic, psychiatric, or renal functional abnormality, as determined by medical history, physical examination, or clinical laboratory screening tests (Phase 2 only), which in the opinion of the investigator, might have interfered with the study objectives.\n* History of any blood or solid organ cancer.\n* History of thrombocytopenic purpura or known bleeding disorder.\n* History of seizures.\n* Known or suspected immunosuppressed or immune deficient condition of any kind.\n* Known Hepatitis B Virus (HBV) or Hepatitis C virus (HCV) infection by self-report (Phase 3) or a positive test for either HBV surface antigen (HBsAg) or HCV antibody using anti-HCV test (Phase 2).\n* Known HIV infection (self-report)\n* Known active tuberculosis or symptoms of active tuberculosis (self-report).\n* History of chronic alcohol abuse and/or illegal drug use.\n* Pregnancy or lactation (a negative pregnancy test was required before administration of study product for all women of childbearing potential).\n* History of Guillain-Barre Syndrome.\n* Any condition in the opinion of the investigator that would have increased the health risk of the subject if he/she participated in the study or interfered with the evaluation of the study objectives.\n\nNote: Minor out-of-range laboratory values no greater than Grade 1 were not considered to be exclusionary at screening.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number and Percentage of Subjects Achieving a Hemagglutination Inhibition (HAI) Titer of ≥1:40","description":"Serum specimens were tested for the presence of HAI antibodies to influenza. The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"79","spread":null},{"groupId":"OG002","value":"81","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"98","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 2: Number and Percentage of Subjects Achieving a Hemagglutination Inhibition (HAI) Titer of ≥1:40","description":"Serum specimens were tested for the presence of HAI antibodies to influenza. The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"42","spread":null},{"groupId":"OG002","value":"56","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 2: Number and Percentage of Subjects Achieving at Least a 4-fold Increase in Hemagglutination Inhibition (HAI) Titer","description":"Serum specimens were tested for the presence of HAI antibodies to influenza on day 1, day 22, and day 43 (day 1 and 22 prior to injection). The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"57","spread":null},{"groupId":"OG002","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"88","spread":null},{"groupId":"OG002","value":"93","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 3: Number and Percentage of Subjects Achieving at Least a 4-fold Increase in Hemagglutination Inhibition (HAI) Titer","description":"Serum specimens were tested for the presence of HAI antibodies to influenza. The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"150","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 2: Geometric Mean Hemagglutination Inhibition (HAI) Titer","description":"Serum specimens were tested for the presence of HAI antibodies to influenza on day 1, day 22, and day 43 (day 1 and 22 prior to injection). The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.48","spread":null},{"groupId":"OG001","value":"5.62","spread":null},{"groupId":"OG002","value":"5.68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.52","spread":null},{"groupId":"OG001","value":"31.67","spread":null},{"groupId":"OG002","value":"42.16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.63","spread":null},{"groupId":"OG001","value":"62.65","spread":null},{"groupId":"OG002","value":"59.20","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 3: Geometric Mean Hemagglutination Inhibition (HAI) Titer","description":"Serum specimens were tested for the presence of HAI antibodies to influenza. The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.04","spread":null},{"groupId":"OG001","value":"5.08","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.20","spread":null},{"groupId":"OG001","value":"27.61","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 2: Geometric Mean Hemagglutination Inhibition (HAI) Titer Ratio, With Respect to Day 1","description":"Serum specimens were tested for the presence of HAI antibodies to influenza on day 1, day 22, and day 43 (day 1 and 22 prior to injection). The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.01","spread":null},{"groupId":"OG001","value":"5.64","spread":null},{"groupId":"OG002","value":"7.42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.03","spread":null},{"groupId":"OG001","value":"11.15","spread":null},{"groupId":"OG002","value":"10.41","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 3: Geometric Mean Hemagglutination Inhibition (HAI) Titer Ratio, With Respect to Day 1","description":"Serum specimens were tested for the presence of HAI antibodies to influenza. The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.01","spread":null},{"groupId":"OG001","value":"5.31","spread":null}]}]}]},{"type":"SECONDARY","title":"Number and Percentage of Subjects Experiencing Reactogenicity","description":"Immediate reactogenicity (30 minutes post-injection) were evaluated on Day 1 and Day 22 and consisted of:\n\n* Inspection of the upper arms for the presence or absence of redness, swelling, hardness, pain, or tenderness; and\n* Documentation of the presence or absence of headache, fever, fatigue/malaise, muscle aches, joint aches, nausea, vomiting, or chills.\n\nImmediate reactogenicity were assessed by a study physician or appropriately trained medical staff.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number and Percentage of Subjects Experiencing Reactogenicity","description":"Reported solicited signs and symptoms were recorded by the subject on the Diary Card from Days 1-7 and Days 22-28 in the study, then evaluated by study physician on Days 8, 22, and 29.The evaluated solicited local reactogenicity events were as follows:\n\n* Size of redness (at site of injection) in centimeters (cm)\n* Size of swelling (at site of injection) in cm\n* Size of induration (hardness at site of injection) in cm\n* Pain (at site of injection)\n* Tenderness (at site of injection)\n\nThe evaluated solicited systemic reactogenicity events were as follows:\n\n* Fever/body temperature (and body location of measurement)\n* Fatigue/malaise\n* Generalized muscle aches\n* Joint aches/pains\n* Chills\n* Nausea\n* Vomiting\n* Headache","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"83","spread":null},{"groupId":"OG002","value":"87","spread":null},{"groupId":"OG003","value":"19","spread":null},{"groupId":"OG004","value":"409","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"83","spread":null},{"groupId":"OG003","value":"36","spread":null},{"groupId":"OG004","value":"286","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"50","spread":null},{"groupId":"OG003","value":"15","spread":null},{"groupId":"OG004","value":"227","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"31","spread":null},{"groupId":"OG002","value":"37","spread":null},{"groupId":"OG003","value":"19","spread":null},{"groupId":"OG004","value":"129","spread":null}]}]}]},{"type":"SECONDARY","title":"Number and Percentage of Subjects Experiencing Unsolicited Adverse Events (AE)","description":"Unsolicited AEs were any AEs that occurred any time after study product was given (temporally related to study product), whether or not deemed \"related\" to the product, and were not solicited. Unsolicited AEs were either observed by study staff while the subject was at a clinic for a study visit or reported by the subject at any time. Any solicited sign or symptom starting after 7 days post-study product injection was recorded as an \"unsolicited AE\".\n\nFor the Phase 2 study, laboratory results were considered AEs when the result was Grade 2 or above.\n\nAny medical condition that was present at the time that the subject was enrolled was not reported as an AE, but was reported as a pre-existing condition on the Medical History Form. However, if this condition occurred with greater frequency or severity during the study, it was recorded as an AE.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"24","spread":null},{"groupId":"OG003","value":"16","spread":null},{"groupId":"OG004","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"11","spread":null},{"groupId":"OG003","value":"16","spread":null},{"groupId":"OG004","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number and Percentage of Subjects Experiencing Unsolicited Serious Adverse Events (SAE)","description":"Defined as an adverse event that led to death, was life-threatening (subject at immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in congenital anomaly/birth defect; resulted in a persistent or significant disability or incapacity.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 2: Number and Percentage of Subjects Achieving at Least a 4-fold Increase in Neutralizing Antibody Titer","description":"The microneutralization (MN) assay is an alternative assay for determining immunologic response to vaccination. It is a highly sensitive assay that can provide information on the ability of induced antibody to neutralize influenza virus. Titers of neutralizing antibodies were expressed as the amount of the greatest dilution of serum giving a neutralization of 50% of tissue cytopathic effects of the virus in the tissue culture.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"57","spread":null},{"groupId":"OG002","value":"63","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 3: Number and Percentage of Subjects Achieving at Least a 4-fold Increase in Neutralizing Antibody Titer","description":"The MN assay is an alternative assay for determining immunologic response to vaccination. It is a highly sensitive assay that can provide information on the ability of induced antibody to neutralize influenza virus. Titers of neutralizing antibodies were expressed as the amount of the greatest dilution of serum giving a neutralization of 50% of tissue cytopathic effects of the virus in the tissue culture.\n\nIn Phase 3, MN assay was conducted in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in order to have at least 200 evaluable subjects receiving IVACFLU A/H5N1 and 40 evaluable subjects receiving placebo.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"114","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 2: Geometric Mean Neutralizing Antibody Titer","description":"The microneutralization (MN) assay is an alternative assay for determining immunologic response to vaccination. It is a highly sensitive assay that can provide information on the ability of induced antibody to neutralize influenza virus. Titers of neutralizing antibodies were expressed as the amount of the greatest dilution of serum giving a neutralization of 50% of tissue cytopathic effects of the virus in the tissue culture.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.15","spread":null},{"groupId":"OG001","value":"7.10","spread":null},{"groupId":"OG002","value":"7.19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.12","spread":null},{"groupId":"OG001","value":"13.78","spread":null},{"groupId":"OG002","value":"29.76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.12","spread":null},{"groupId":"OG001","value":"29.76","spread":null},{"groupId":"OG002","value":"28.48","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 3: Geometric Mean Neutralizing Antibody Titer","description":"Serum specimens were tested for the presence of HAI antibodies to influenza. The HAI assay was conducted using serum samples from all the subjects in Phase 2 of the study and in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in Phase 3 in order to have at least 200 evaluable subjects receiving IVACFLU-A/H5N1 and 40 evaluable subjects receiving placebo, at the end of study.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.07","spread":null},{"groupId":"OG001","value":"7.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.07","spread":null},{"groupId":"OG001","value":"26.16","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 2: Geometric Mean Neutralizing Antibody Titer Ratio, With Respect to Day 1","description":"The microneutralization (MN) assay is an alternative assay for determining immunologic response to vaccination. It is a highly sensitive assay that can provide information on the ability of induced antibody to neutralize influenza virus. Titers of neutralizing antibodies were expressed as the amount of the greatest dilution of serum giving a neutralization of 50% of tissue cytopathic effects of the virus in the tissue culture.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":null},{"groupId":"OG001","value":"1.94","spread":null},{"groupId":"OG002","value":"2.02","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":null},{"groupId":"OG001","value":"4.19","spread":null},{"groupId":"OG002","value":"3.96","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase 3: Geometric Mean Neutralizing Antibody Titer Ratio, With Respect to Day 1","description":"The MN assay is an alternative assay for determining immunologic response to vaccination. It is a highly sensitive assay that can provide information on the ability of induced antibody to neutralize influenza virus. Titers of neutralizing antibodies were expressed as the amount of the greatest dilution of serum giving a neutralization of 50% of tissue cytopathic effects of the virus in the tissue culture.\n\nIn Phase 3, MN assay was conducted in a subset of approximately 270 subjects receiving the IVACFLU-A/H5N1 vaccine (vaccinees) and placebo from one study site in order to have at least 200 evaluable subjects receiving IVACFLU A/H5N1 and 40 evaluable subjects receiving placebo.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":null},{"groupId":"OG001","value":"3.70","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":100},"commonTop":["Oropharyngeal pain","Pharyngitis","Viral upper respiratory tract infection","Hypertension","Nasopharyngitis"]}}}